샘플 요청 목록

 카트 문의
시장보고서
상품코드
1798291

세계의 혈관 운동 증상 시장

Vasomotor Symptoms
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 376 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 혈관 운동 증상 시장은 2030년까지 55억 달러에 이를 전망

2024년에 39억 달러로 추정되는 혈관 운동 증상 세계 시장은 2024-2030년 분석 기간에 CAGR 5.9%로 성장하여 2030년에는 55억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 에스트로겐 요법은 CAGR 7.7%를 나타내고, 분석 기간 종료시에는 15억 달러에 이를 것으로 예측됩니다. 프로게스테론 요법 분야의 성장률은 분석 기간중 CAGR 4.0%로 추정됩니다.

미국 시장은 11억 달러로 추정, 중국은 CAGR 9.5%로 성장 예측

미국의 혈관 운동 증상 시장은 2024년에 11억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 11억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 9.5%로 추정됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 2.7%와 5.8%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 3.8%를 보일 전망입니다.

세계의 혈관 운동 증상 시장 - 주요 동향과 촉진요인 정리

왜 지금 혈관 운동 증상이 임상 및 제약 업계에서 주목받는 이유는 무엇인가?

혈관운동증상(VMS)은 주로 안면홍조와 식은땀을 특징으로 하는 갱년기의 가장 흔하고 파괴적인 증상 중 하나입니다. 전 세계적으로 폐경기 및 폐경 후 여성의 최대 80%가 겪고 있으며, 이러한 증상은 임상에서 충분히 진단되지 않고 충분히 다루어지지 않고 있습니다. 그러나 최근 VMS를 단순한 불편함이 아닌 수면, 심혈관계 기능, 삶의 질에 심각한 영향을 미치는 질환으로 치료할 필요성에 대한 의학적 공감대가 형성되고 있습니다. 이러한 패러다임의 변화로 인해 다양한 약물군별, 약물 전달 형태에 따른 치료 옵션에 대한 수요가 증가하고 있습니다.

호르몬 대체요법(HRT)은 여전히 많은 경우에 표준으로 사용되고 있지만, 일부 환자군에서는 유방암, 혈전색전증, 심혈관계 질환과 관련된 위험으로 인해 사용이 제한되는 경우가 많습니다. 그 결과, 선택적 세로토닌 재흡수 억제제(SSRI), 세로토닌 노르에피네프린 재흡수 억제제(SNRI), 최근에는 뉴로키닌-3(NK3) 수용체 길항제 등 호르몬 외의 중재 약물에 대한 수요가 증가하고 있습니다. 이러한 치료법의 확대는 스크리닝 강화, 홍보 캠페인, 규제 당국의 승인 등을 수반하며, 특히 북미와 유럽에서 VMS 치료의 전망이 확대되고 있습니다.

약물 전달 기술 혁신이 VMS 치료를 어떻게 강화할 것인가?

비호르몬 치료와 표적치료에 대한 관심이 높아지면서 혈관운동증상 치료제 혁신 파이프라인이 재편되고 있습니다. 경구용 NK3 수용체 길항제인 페졸리넨트의 승인은 VMS의 원인으로 여겨지는 체온 조절 기능 장애를 직접 표적으로 삼는다는 점에서 중요한 이정표가 될 것입니다. 이 NK3 수용체 길항제 시장 진입은 다른 제약회사들의 동종 약물 개발을 촉발시켰고, 현재 여러 NK3 수용체 길항제가 임상 II상 및 임상 III상 단계에 있습니다. 이러한 기술 혁신은 호르몬 요법이 금기인 환자들에게 매우 중요하며, VMS 치료의 새로운 표준 치료법이 될 수 있습니다.

약물 전달 형태 또한 복약 순응도와 환자 선호도를 향상시키기 위해 진화하고 있습니다. 경피 패치, 질 링, 외용 스프레이는 기존 경구약과 함께 시장 점유율을 확대하고 있으며, 전신 증상과 국소 증상 모두에 대응하고 있습니다. 처방전 기반 솔루션을 보완하기 위해 일반의약품(OTC) 및 건강보조식품 분야, 특히 블랙코호시, 레드클로버, 콩 이소플라본 등 식물성 의약품이 꾸준히 성장하고 있지만, 임상적 효능은 여전히 엇갈리고 있습니다. 또한, VMS를 통한 수면장애나 기분장애를 대상으로 하는 CBT 기반 앱을 포함한 디지털 치료제가 특히 디지털 리터러시가 높은 시장에서 보조 도구로 부상하고 있습니다.

시장 도입이 가속화되고 있는 시장과 성장을 주도하는 환자층은?

혈관운동증상치료제가 가장 성숙한 시장은 갱년기 질환에 대한 인식과 의료 접근성이 상대적으로 높은 미국, 캐나다, 유럽 국가들입니다. 미국에서는 소비자 직접 판매(DTC) 플랫폼과 펨테크 기업들이 가상 진료, 원격 처방, 실험실 검사와 번들로 제공되는 VMS에 특화된 솔루션 등 개인화된 갱년기 관리를 적극적으로 추진하고 있습니다. 갱년기 여성을 타겟으로 한 브랜드가 개별적이고 품격 있는 지원 서비스를 제공하여 상업적으로 성공하면서 수면 보조제, 정신 건강, 성 건강 등 인접 카테고리에 대한 수요가 강화되고 있습니다.

아시아태평양과 라틴아메리카에서는 인구 구조의 변화로 인해 폐경기 인구가 증가하고 폐경기에 대한 편견이 사라지기 시작하면서 VMS 시장이 성장세를 보이고 있습니다. 일본, 한국, 중국의 도시지역은 고성장 허브로 부상하고 있으며, 서유럽식 요법이 현지인의 취향에 맞게 변화하고 있습니다. 또한, 건강 의식이 높은 40-50대 갱년기 여성이라는 젊은 층이 특히 민간의료 시스템에서 중요한 소비자 그룹으로 부상하고 있습니다. 이러한 여성들은 조기 개입, 생활습관에 따른 치료 옵션, 호르몬 변화를 관리할 수 있는 전인적 접근법을 원하고 있습니다.

VMS 세계 시장 확대의 원동력은?

혈관운동증상 시장의 성장을 견인하는 몇 가지 요인은 여성의 평균 수명 증가, 갱년기 관련 헬스케어에 대한 개방성 증가, 빠르게 확장되는 제품 파이프라인 등 여러 가지 요인이 있습니다. 여성은 인생의 3분의 1을 폐경기 이후에 보내므로 장기적이고 안전하고 효과적인 치료법에 대한 수요가 증가하고 있습니다. 인식 개선 캠페인 강화, 고용주가 후원하는 웰니스 프로그램, 소셜 플랫폼을 통한 갱년기 질환의 낙인찍기 등은 모두 치료를 받기 위한 행동을 촉구하고 있습니다. 의료 보험사와 의료 서비스 제공업체들도 갱년기 관리를 보다 광범위한 여성 건강 서비스에 통합하기 시작했습니다.

의약품의 혁신, 특히 비호르몬 의약품의 혁신은 여전히 중요한 촉진요인입니다. 페소리넨터와 같은 블록버스터 치료제의 진입은 중견 및 대형 제약사들의 투자를 자극하고 있습니다. 이 분야는 그동안 미충족 수요가 있었기 때문에 규제 당국도 신속한 승인에 긍정적인 입장을 보이고 있습니다. 펨텍과 디지털 치료제의 등장은 더욱 가속화되고 있으며, VMS 치료를 더욱 친숙하게 만드는 확장 가능하고 개인화된 솔루션을 제공합니다. 이러한 변화를 종합하면, VMS 시장은 전 세계적으로 크게 확대될 것이며, 처방약과 소비자 웰빙 경로 모두 장기적인 궤도에 기여할 것입니다.

부문

요법 유형(에스트로겐, 프로게스테론, 병용, OTC 호르몬, 항우울제, 기타 요법 유형), 유통 채널(병원 약국, 소매 약국, 드럭스토어), 최종사용자(병원 및 클리닉, 전문 시설, 기타 최종사용자)

조사 대상 기업 예

  • Astellas Pharma
  • Bayer AG
  • Biogen(partnering)
  • Bionovo
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Gedeon Richter
  • GlaxoSmithKline(GSK)
  • HRA Pharma
  • Johnson & Johnson
  • Merck & Co.
  • NeRRe Therapeutics
  • NeRRe Therapeutics(dual)
  • Noema Pharma
  • Noven Pharmaceuticals
  • Novo Nordisk
  • Ogeda(now Astellas)
  • Pfizer(Duavee)
  • Pfizer Inc.
  • Shionogi & Co.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.09.03

Global Vasomotor Symptoms Market to Reach US$5.5 Billion by 2030

The global market for Vasomotor Symptoms estimated at US$3.9 Billion in the year 2024, is expected to reach US$5.5 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Estrogen Therapy, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$1.5 Billion by the end of the analysis period. Growth in the Progesterone Therapy segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 9.5% CAGR

The Vasomotor Symptoms market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 9.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Vasomotor Symptoms Market - Key Trends & Drivers Summarized

Why Are Vasomotor Symptoms Garnering Greater Clinical and Pharmaceutical Attention Today?

Vasomotor symptoms (VMS), primarily characterized by hot flashes and night sweats, are among the most prevalent and disruptive manifestations of menopause. Affecting up to 80% of perimenopausal and postmenopausal women globally, these symptoms have traditionally been underdiagnosed and under-addressed in clinical settings. However, recent years have witnessed a growing medical consensus on the need to treat VMS not merely as a discomfort but as a condition with significant impacts on sleep, cardiovascular function, and quality of life. This paradigm shift is driving increased demand for therapeutic options across multiple drug classes and delivery formats.

While hormone replacement therapy (HRT) remains the gold standard in many cases, its use is often limited due to risks associated with breast cancer, thromboembolism, and cardiovascular disease in some patient groups. As a result, there is rising demand for non-hormonal interventions including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and more recently, neurokinin-3 (NK3) receptor antagonists. This therapeutic expansion is accompanied by heightened screening, awareness campaigns, and regulatory approvals that together are broadening the VMS treatment landscape, particularly in North America and Europe.

How Is Innovation in Drug Development and Delivery Enhancing VMS Management?

The pharmaceutical innovation pipeline for vasomotor symptoms is being reshaped by a surge in interest in non-hormonal and targeted therapies. The approval of fezolinetant, an oral NK3 receptor antagonist, marks a significant milestone as it directly targets thermoregulatory dysfunction believed to cause VMS. Its market entry has catalyzed development in similar classes by other pharmaceutical players, with multiple NK3 antagonists currently in Phase II and III trials. These innovations are pivotal for patients contraindicated for hormone therapy and may define a new standard of care in VMS treatment.

Drug delivery formats are also evolving to improve adherence and patient preference. Transdermal patches, vaginal rings, and topical sprays are gaining market share alongside traditional oral pills, addressing both systemic and localized symptoms. Complementary to prescription-based solutions, the over-the-counter (OTC) and nutraceutical segments are seeing robust activity, particularly in botanicals such as black cohosh, red clover, and soy isoflavones, though clinical efficacy remains mixed. Additionally, digital therapeutics including CBT-based apps targeting sleep and mood disturbances from VMS are emerging as adjunct tools, especially in markets with high digital literacy.

Where Is Market Adoption Accelerating and What Patient Segments Are Driving Growth?

The most mature markets for vasomotor symptom therapies are in the U.S., Canada, and several European nations where menopause awareness and healthcare access are relatively high. In the U.S., direct-to-consumer (DTC) platforms and femtech companies are aggressively pushing personalized menopause care, including VMS-specific solutions bundled with virtual consultations, remote prescriptions, and lab testing. The commercial success of brands targeting menopausal women with discrete and dignified support services is reinforcing demand in adjacent categories such as sleep aids, mental health, and sexual wellness.

In Asia-Pacific and Latin America, the VMS market is gaining traction as demographic transitions increase the menopausal population, and stigma around menopause begins to erode. Urban centers in Japan, South Korea, and China are emerging as high-growth hubs where Western therapies are being adapted to local preferences. Additionally, a younger demographic of health-conscious perimenopausal women aged 40-50 is emerging as a key consumer group, particularly in private healthcare systems. These women are seeking early interventions, lifestyle-aligned treatment options, and holistic approaches to managing hormonal changes.

What Forces Are Powering the Expansion of the Global VMS Market?

The growth in the vasomotor symptoms market is driven by several factors, including increasing female life expectancy, greater openness to menopause-related healthcare, and a rapidly expanding product pipeline. As women spend a third of their lives in postmenopause, the demand for long-term, safe, and effective treatments is growing. Enhanced awareness campaigns, employer-sponsored wellness programs, and the destigmatization of menopause across social platforms are all encouraging treatment-seeking behavior. Health insurers and providers are also beginning to integrate menopause care into broader women’s health services.

Pharmaceutical innovation-especially in non-hormonal drug classes-remains a critical growth driver. The entry of blockbuster therapies such as fezolinetant has catalyzed investment from mid- and large-cap pharmaceutical companies. Regulatory bodies are increasingly receptive to fast-track approvals given the previously unmet needs in this segment. The rise of femtech and digital therapeutics is adding further momentum, offering scalable and personalized solutions that make VMS care more accessible. Collectively, these shifts point toward a significant expansion of the VMS market globally, with both prescription and consumer wellness pathways contributing to its long-term trajectory.

SCOPE OF STUDY:

The report analyzes the Vasomotor Symptoms market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy Type (Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy, Other Therapy Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores); End-User (Hospitals & Clinics End-User, Specialty Centers End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Astellas Pharma
  • Bayer AG
  • Biogen (partnering)
  • Bionovo
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Gedeon Richter
  • GlaxoSmithKline (GSK)
  • HRA Pharma
  • Johnson & Johnson
  • Merck & Co.
  • NeRRe Therapeutics
  • NeRRe Therapeutics (dual)
  • Noema Pharma
  • Noven Pharmaceuticals
  • Novo Nordisk
  • Ogeda (now Astellas)
  • Pfizer (Duavee)
  • Pfizer Inc.
  • Shionogi & Co.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Vasomotor Symptoms - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness of Menopausal Health Throws the Spotlight on Vasomotor Symptom Management Solutions
    • Increasing Female Geriatric Population Spurs Demand for Effective Therapies to Treat Hot Flashes and Night Sweats
    • Shift Toward Non-Hormonal Treatment Options Expands Addressable Market for Alternative and Natural Remedies
    • Increased Focus on Women's Health Equity Strengthens the Business Case for Targeted VMS Therapeutics
    • Innovation in Neurokinin Receptor Antagonists Drives Growth in Prescription-Based Non-Hormonal VMS Treatments
    • Growth in Digital Health and Telemedicine Enhances Access to VMS Consultations and Remote Prescription Services
    • Consumer Shift Toward Personalized Health Fuels Demand for Tailored Hormone Therapy and Functional Medicine
    • Management Products
    • Research Linking VMS with Long-Term Cardiovascular and Metabolic Risk Increases Screening and Intervention Rates
    • Innovation in Wearable Cooling Devices and Smart Clothing Adds Momentum to Non-Pharmacologic Solutions
    • Retail Health Clinics and Pharmacies Drive Accessibility of Menopause and VMS-Related Treatment Avenues
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Vasomotor Symptoms Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Vasomotor Symptoms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Vasomotor Symptoms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Vasomotor Symptoms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Estrogen Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Estrogen Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Estrogen Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Progesterone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Progesterone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Progesterone Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Combination Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Combination Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Combination Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for OTC Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for OTC Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for OTC Hormone Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Anti-Depressants Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Anti-Depressants Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Anti-Depressants Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Therapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Therapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Therapy Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals & Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospitals & Clinics End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Specialty Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Specialty Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Specialty Centers End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Drug Stores by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Drug Stores by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Drug Stores by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Vasomotor Symptoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • JAPAN
    • Vasomotor Symptoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • CHINA
    • Vasomotor Symptoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: China 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • EUROPE
    • Vasomotor Symptoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Vasomotor Symptoms by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Vasomotor Symptoms by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Vasomotor Symptoms by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • FRANCE
    • Vasomotor Symptoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: France 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • GERMANY
    • Vasomotor Symptoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Vasomotor Symptoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Vasomotor Symptoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Vasomotor Symptoms by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Vasomotor Symptoms by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Vasomotor Symptoms by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Vasomotor Symptoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • INDIA
    • Vasomotor Symptoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: India 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Vasomotor Symptoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Vasomotor Symptoms by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Vasomotor Symptoms by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Vasomotor Symptoms by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Vasomotor Symptoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Vasomotor Symptoms by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Vasomotor Symptoms by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Vasomotor Symptoms by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030
  • AFRICA
    • Vasomotor Symptoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Vasomotor Symptoms by Therapy Type - Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Vasomotor Symptoms by Therapy Type - Percentage Breakdown of Value Sales for Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy and Other Therapy Types for the Years 2014, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Vasomotor Symptoms by End-user - Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Vasomotor Symptoms by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics End-User, Specialty Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Vasomotor Symptoms by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Drug Stores Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Vasomotor Symptoms by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Drug Stores for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제